Assessing Immunogenicity & Clinical Activity of Neoantigen Vaccine to Design Successful Vaccines

Time: 9:30 am
day: Pre-Conference Focus Day


  • How to predict immunogenicity of antigens by reviewing factors such as the antigen’s chemical properties, its ability to bind to MHC molecules, and its presentation to T cells
  • Reviewing the available clinical or pre-clinical data to show the advances in neoantigen vaccines vs traditional vaccine and mRNA vaccines
  • Highlighting that the neoantigen vaccine personalized approach has shown great potential in eliciting strong and specific immune responses against cancer cells